CR Sanjiu

同壁财经 · May 28 at 08:37 PM

CR Sanjiu will distribute over 1.7 billion in cash in 2025, highlighting a high dividend payout that underscores its dividend characteristics

Wallstreetcn · Apr 14 at 07:17 AM

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

AASTOCKS · Mar 22 at 08:35 PM

China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMB

AASTOCKS · Feb 8 at 04:56 AM

CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%

36Kr · Feb 4 at 10:42 PM

CR Sanjiu's registered capital increased to approximately 1.66 billion yuan

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited